Israel Gynecology Drugs Market to be Dominated by Non-hormonal Therapy through 2028
Rise in the number of gynecological
cancers and an increase in healthcare expenditure in the country are expected
to drive the growth of the Israel gynecology drugs market during the forecast
period, 2024-2028.
According to TechSci Research
report, “Israel Gynecology Drugs Market- Industry
Size, Share, Trends, Competition, Forecast and Opportunities, 2028”, the bolstering growth of the
Israel gynecology drugs market can be attributed to a range of factors,
including the prevalence of gynecological disorders, increasing awareness and
education, aging population, lifestyle factors, and advances in medical technology.
In Israel, drugs are regulated by the Ministry of Health and are subject to
strict approval processes. The ministry evaluates drugs for safety, efficacy,
and quality before they are authorized for use in the country. Gynecology drugs
are included in this process and are subject to the same regulations as other
pharmaceutical products. Drugs can be obtained through a variety of channels,
including pharmacies, hospitals, and clinics in the country. In addition to
traditional pharmaceutical drugs, Israel is also known for its research and
development of medical cannabis. In recent years, medical cannabis has been
used to treat a variety of gynecological conditions such as endometriosis,
dysmenorrhea, and menopausal symptoms which are some of the most common
gynecological disorders prevailing among the female population of the country.
Hormone replacement therapy
(HRT) is also becoming popular for treating symptoms of menopause, such as hot
flashes, vaginal dryness, and mood swings. It involves taking estrogen and
sometimes progestin to replace the hormones that are no longer produced by the
ovaries. HRT is available both by prescription and over the counter in various
forms in Israel, including pills, patches, and creams for treating any
gynecological disorder.
Gynecology drugs are generally
designed to treat a wide range of female reproductive health issues, such as
menstrual disorders, fertility problems, infections, and menopausal symptoms. Gynecological disorders are common among women
of all ages. The prevalence of infertility in women with PCOS can vary between
70 and 80%. For instance, menstrual disorders affect more than 10% of women,
while up to 10% of couples experience fertility problems. These disorders can
have a significant impact on a woman's quality of life and may require medical
intervention, which often involves the use of gynecology drugs. Women today are
more informed and educated about their reproductive health. They are more
likely to seek medical advice and treatment for gynecological issues, which has
led to an increase in the demand for gynecology drugs. As women age, they are
more likely to experience gynecological problems such as menopause, which can
cause a range of symptoms such as vaginal dryness. This has led to an increase
in the demand for drugs that can help manage these symptoms. Lifestyle factors such as stress, poor diet,
lack of exercise, and exposure to environmental toxins can negatively impact
women's reproductive health. As a result, there is a growing demand for drugs
that can help manage these factors and prevent or treat gynecological
disorders. Advances in medical technology have led to the development of new
and more effective gynecology drugs. For instance, hormonal contraceptives have
become more widely available and are now available in a range of formulations
to suit different needs. As women continue to prioritize their reproductive
health, the demand for gynecology drugs is likely to remain strong.
Polycystic ovary syndrome
(PCOS) is a common hormonal disorder that affects women of reproductive age across
the world. However, the prevalence of PCOS in Israel is not well documented,
and estimates vary widely depending on the diagnostic criteria used. PCOS can
be diagnosed and managed by healthcare providers in Israel, and treatment
options may include lifestyle changes, such as weight loss, exercise, and
medications, to regulate menstrual cycles and reduce androgen levels, thereby
increasing the demand for gynecological drugs for treatment. Women with PCOS in
Israel can also receive fertility treatments if needed to achieve pregnancy by
providing gynecological medication.
Browse over 26 market data Figures spread through 91 Pages and an in-depth TOC on "Israel Gynecology Drugs Market”
It is important for women
with PCOS to get regular consultation with their healthcare provider/
physicians to manage their symptoms of PCOS and reduce their risk for long-term
health complications, such as diabetes and cardiovascular disease which is
becoming more prevalent in the country.
Telemedicine is already a
growing trend, and it is likely to continue to expand in the coming years. This
can include more online consultations with healthcare professionals, including
pharmacists, and greater use of remote monitoring technology. As data analytics
and artificial intelligence (AI) continue to advance, online platforms for gynecology
drugs may become more personalized, taking into account individual health
information, genetic data, and lifestyle factors to provide tailored
recommendations and treatments.
The future of gynecology drugs looks promising as advances
in research and technology continue to bring new treatment options to the
market. Here are a few areas where growth and innovation can be witnessed in
the coming years.
The market for gynecology drugs grew historically as a
result of an increase in the introduction of medications with novel mechanisms,
an increase in menopause education and awareness tools, an increase in
long-acting reversible contraceptives, a change in lifestyles, an increase in
healthcare awareness and spending, government initiatives, and an increase in
pharmaceutical R&D spending. However, lack of scientific understanding of
PCOS, safety issues with HRT and hormonal contraceptives, limited access to
healthcare, high costs associated with drug approval, drug patent expirations,
price pressure from regulators, and regulatory changes are expected to restrain
the growth of the Israel gynecology drugs market during the forecast period
2024-2028.
The Israel gynecology drugs
market is segmented into therapeutics, indication, distribution channel,
regional distribution, and company.
Based
on therapeutics, the market is segmented into non-hormonal therapy and hormonal
therapy. Non-hormonal therapy is expected to dominate the market during the
forecast period because non-hormonal therapies are often more affordable than
hormonal therapy, which can be a significant advantage for women who do not
have insurance coverage or cannot afford the cost of prescription medications. Many
non-hormonal therapies, such as non-steroidal anti-inflammatory drugs (NSAIDs),
are available over the counter, making them easily accessible to women. Hormonal
therapy is typically not recommended for long-term use due to the risk of side
effects. Non-hormonal therapies can be used long-term without these concerns.
Based on distribution
channel, the Israel gynecology drugs market is segmented into retail
pharmacies, hospital pharmacies, and online pharmacies. Retail pharmacies are
expected to boost the demand for gynecology drugs because retail pharmacies are
the most used distribution channel for medicine purchase. They offer a wide
range of medications, both prescription and over the counter. Online pharmacies
are expected to be the fastest growing segment in the coming years owing to its
increasing popularity in recent years, offering a convenient way for consumers
to purchase medications from the comfort of their own homes. Moreover, the availability
of different generic medication present in a single platform can make the use
of gynecology drugs efficient and cost-saving.
Major companies operating in the
Israel gynecology drugs market are:
- Teva Pharmaceutical Industries Ltd.
- Pfizer Inc.
- GlaxoSmithKline plc
- AstraZeneca Israel
- Johnson & Johnson
- Bayer Israel Ltd.
- Abbott Laboratories Ltd.
- Eli Lilly Israel Ltd.
- AbbVie Inc.
- OCON Medical
Download Free Sample Report
Customers
can also request for 10% free customization on this report.
“The increasing incidence of gynecological cancer, polycystic
ovary syndrome, and endometriosis in the country is boosting the demand for
gynecology drugs in Israel. The women in Israel are becoming more aware of the female
hygiene and health which is also driving the demand for gynecology drugs. The
market will be driven by increased investment to comprehend the processes of
endometriosis and its treatment, as well as a rise in knowledge and usage of
HRT and contraceptives, age-related increase in gynecological cancers, a rise
in ovarian cancer, prevalence of gynecological diseases, and a rise in
healthcare expenditure,” said Mr. Karan Chechi, Research Director with TechSci
Research, a research-based management consulting firm.
“Israel Gynecology Drugs
Market By Therapeutics (Non-Hormonal Therapy vs. Hormonal Therapy), By
Indication (Contraception, Gynecology Infections, Female Infertility,
Postmenopausal disorders, Polycystic Ovary Syndrome, Osteoporosis, Gynecology
Cancer, Endometriosis, Others), By Distribution Channel (Retail Pharmacies,
Hospital Pharmacies, Online Pharmacies), By Region, Competition, Forecast and
Opportunities, 2028”, has evaluated the future
growth potential of the Israel gynecology drugs market and provides statistics
& information on market size, structure, and future market growth. The
report intends to provide cutting-edge market intelligence and help decision
makers take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in the Israel gynecology drugs market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com